Also, only one dose level of GM1 was used in this study and although the dose used was the same that has been shown to be neuroprotective in MPTP mouse models of PD, it is possible that the dose used may not have been optimal in the rat AAV-A53T α-synuclein model. This evidence concerns the gene SNCA and Parkinson disease.